Tadalafil study for pediatric PAH on efficacy, safety and pharmacodynamics

Tadalafil study for pediatric PAH on efficacy, safety and pharmacodynamics - Tadalafil study for pediatric PAH

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005973

Enrollment

Registered

2011-08-01

Start date

2011-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pediatric pulmonary arterial hypertension

Interventions

single oral administration of tadalafil 1mg/kg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: PAH

Exclusion criteria

Exclusion criteria: Those who are contraindicated for tadalafil

Design outcomes

Primary

Measure	Time frame
tadalafil activity(30min, 1hr, 2hr, 3hr, 4 or 5hr) after administration mean pulmonary arterial pressure and pulmonary arterial resistance of the same time points	—

Secondary

Measure	Time frame
cyclic GMP level blood pressure, heart rate adverse effects (headache, flushing)	—

Countries

Japan

Contacts

Public ContactOsamu, Yamada

National Cerebral and Cardiovascular Center Department of Pediatric Cardiology

yamadao@hsp.ncvc.go.jp06-6833-5012

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026